Anti-Hypertensive Drugs - Slovenia

Slovenia

In Slovenia, the revenue in the Anti-Hypertensive Drugs market is estimated to reach US$9.03m in the year 2024.
It is projected that the revenue will experience an annual growth rate of -0.14% between 2024 and 2028, leading to a market volume of US$8.98m by 2028.
When comparing globally, United States is expected to generate the highest revenue of US$12,290.00m in 2024.
Slovenia's anti-hypertensive drug market is witnessing a surge in demand due to the country's aging population and increasing prevalence of hypertension.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Slovenia has been steadily growing in recent years, driven by several factors unique to the region.

Customer preferences: Slovenian customers have shown a growing preference for generic drugs over branded ones, due to their lower cost and comparable efficacy. This has led to an increase in the availability of generic anti-hypertensive drugs in the market, which has further fueled their adoption.

Trends in the market: The market for anti-hypertensive drugs in Slovenia is experiencing a shift towards combination therapies, as opposed to single-drug treatments. This trend is driven by the desire for more effective and convenient treatment options, as well as the increasing prevalence of hypertension in the country. Additionally, there has been a growing interest in natural remedies and alternative therapies for hypertension, which has led to the emergence of new products in the market.

Local special circumstances: Slovenia has a well-established public healthcare system, which provides universal coverage to its citizens. This has led to a high level of demand for anti-hypertensive drugs, as hypertension is a prevalent condition in the country. Additionally, the government has implemented policies to promote the use of generic drugs, which has further boosted their adoption in the market.

Underlying macroeconomic factors: The Slovenian economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. This has contributed to the growth of the anti-hypertensive drugs market, as customers are more willing to invest in their health. Additionally, the aging demographic in the country has led to a higher prevalence of hypertension, which has further driven demand for these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.